Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

Next Previous
X
Search
Trial Profile

Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabedersen (Primary) ; Carmustine; Lomustine; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPPHIRE
  • Sponsors Isarna Therapeutics

    • Most Recent Events

    • 30 Jul 2022 This trial has been completed in France (Date of the global end of the trial : 10-Jan-2012), according to European Clinical Trials Database record.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003686).
    • 28 Mar 2012 Actual patient number is 27 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top